Cleveland Clinic

AKASA Launches Autonomous AI Coding Covering 10% of U.S. Discharges

South San Francisco, Calif. – October 02, 2026 -- AKASA has launched an autonomous AI platform for inpatient medical coding and clinical documentation integrity (CDI), expanding beyond its existing prebill review tools after inpatient volume processed by the company grew nearly 6x over the past year.

AKASA's health system customers now cover 10% of U.S. inpatient discharges

The company's customer base collectively represents more than $180 billion in aggregate net patient revenue and roughly 10% of all U.S. inpatient discharges. The growth has been driven by adoption of AKASA's existing AI-powered prebill review products, which the company says created the volume and performance data needed to move into fully autonomous coding.

Anixa Biosciences CEO, Trial Patient to Discuss Breast Cancer Vaccine on Bloomberg TV

San Jose, Calif. – September 14, 2026 -- Anixa Biosciences, Inc. (NASDAQ: ANIX) confirmed that Bloomberg TV will air an interview with Chairman and CEO Dr. Amit Kumar and breast cancer vaccine trial patient Sherie Steinberg this Saturday, September 12, at 7:00 PM ET, reaching an estimated 73 million U.S. homes.

Bloomberg TV segment to spotlight breast cancer vaccine data and patient outcomes

The interview will air on the RedChip Small Stocks, Big Money show and is also available online. Dr. Kumar is expected to detail recent progress in Anixa's cancer vaccine development program, including a breast cancer vaccine designed for three applications: treating existing disease, preventing recurrence, and reducing the risk of initial onset in high-risk patients.

IBM, Cleveland Clinic, RIKEN Simulate 12,635-Atom Protein via Quantum

Cleveland – September 13, 2026 -- A research team from Cleveland Clinic, RIKEN and IBM has been named a finalist for the 2026 ACM Gordon Bell Prize after simulating a 12,635-atom protein complex, the largest biologically meaningful molecule ever modeled using quantum computers. The winner will be announced at SC26 in Chicago, running Nov. 15-20, 2026.

Quantum-classical hybrid method scales computation 40-fold in under a year

The team's approach, called quantum-centric supercomputing, combines IBM Quantum Heron processors with classical supercomputers Fugaku and Miyabi-G, operated respectively by RIKEN and a University of Tokyo-University of Tsukuba consortium. The quantum systems executed up to 94 qubits and nearly 6,000 quantum operations on portions of the calculation critical to accuracy, while the classical machines reassembled full molecular representations.